Gothenburg-headquartered Cellink has gone from a start-up to one of the world’s leading 3D bioprinting firms in just four years; firmly positioning Sweden at the forefront of this potentially revolutionary…
Meghann Chilcott offers an introductory look at the potential of customer data platforms (CDPs) to transform the way pharmacy marketers reach out to an increasingly online customer base in the…
Carla Smith outlines the role that a value-based care (VBC) approach can have on both reducing healthcare costs and improving overall care delivery to patients in the USA. Smith highlights…
Aditya Bhattacharji takes a look at the potentially damaging impact of political uncertainty across Europe – including the impending exit of the UK from the European Union – on pharmaceutical…
David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness month. Alzheimer’s disease is a complex chronic disease…
On May 30th, and with much fanfare, Pfizer Upjohn officially inaugurated its global headquarters in the heart of Shanghai, China. Following a global re-organization mid-2018, Pfizer now operates three business…
David Bearman makes the historical case to be once again considered as a medicine across the USA, noting that economic – rather than health – concerns were behind the creation…
Taiwan boasts one of the most sophisticated and comprehensive public health systems in Asia. However, mounting costs and the pressures of a rapidly ageing population mean that the National Health…
Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, examines Algeria’s recent issues around medicine shortages, its root causes, and the measure being taken to counter it.…
Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps…
Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful implementations, and explains why policy updates are so important to ensuring…
Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA. Here, Davis argues that the generics…
See our Cookie Privacy Policy Here
